214 related articles for article (PubMed ID: 16226489)
1. Paradoxical exacerbation of combined hyperlipidemia in human apolipoprotein A-II transgenic mice treated with fenofibrate.
Ribas V; Palomer X; Roglans N; Rotllan N; Fievet C; Tailleux A; Julve J; Laguna JC; Blanco-Vaca F; Escolà-Gil JC
Biochim Biophys Acta; 2005 Dec; 1737(2-3):130-7. PubMed ID: 16226489
[TBL] [Abstract][Full Text] [Related]
2. Expression of human apolipoprotein A-II in apolipoprotein E-deficient mice induces features of familial combined hyperlipidemia.
Escolà-Gil JC; Julve J; Marzal-Casacuberta A; Ordóñez-Llanos J; González-Sastre F; Blanco-Vaca F
J Lipid Res; 2000 Aug; 41(8):1328-38. PubMed ID: 10946021
[TBL] [Abstract][Full Text] [Related]
3. Increased production of very-low-density lipoproteins in transgenic mice overexpressing human apolipoprotein A-II and fed with a high-fat diet.
Julve J; Escolà-Gil JC; Marzal-Casacuberta A; Ordóñez-Llanos J; González-Sastre F; Blanco-Vaca F
Biochim Biophys Acta; 2000 Nov; 1488(3):233-44. PubMed ID: 11082533
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptor alpha is not rate-limiting for the lipoprotein-lowering action of fish oil.
Dallongeville J; Baugé E; Tailleux A; Peters JM; Gonzalez FJ; Fruchart JC; Staels B
J Biol Chem; 2001 Feb; 276(7):4634-9. PubMed ID: 11050100
[TBL] [Abstract][Full Text] [Related]
5. Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome.
Julve J; Escolà-Gil JC; Rotllan N; Fiévet C; Vallez E; de la Torre C; Ribas V; Sloan JH; Blanco-Vaca F
Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):232-8. PubMed ID: 19910634
[TBL] [Abstract][Full Text] [Related]
6. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.
Ribas V; Sánchez-Quesada JL; Antón R; Camacho M; Julve J; Escolà-Gil JC; Vila L; Ordóñez-Llanos J; Blanco-Vaca F
Circ Res; 2004 Oct; 95(8):789-97. PubMed ID: 15388641
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of human apolipoprotein A-II in mice induces hypertriglyceridemia due to defective very low density lipoprotein hydrolysis.
Boisfer E; Lambert G; Atger V; Tran NQ; Pastier D; Benetollo C; Trottier JF; Beaucamps I; Antonucci M; Laplaud M; Griglio S; Chambaz J; Kalopissis AD
J Biol Chem; 1999 Apr; 274(17):11564-72. PubMed ID: 10206963
[TBL] [Abstract][Full Text] [Related]
8. Expression of human apoAII in transgenic rabbits leads to dyslipidemia: a new model for combined hyperlipidemia.
Koike T; Kitajima S; Yu Y; Li Y; Nishijima K; Liu E; Sun H; Waqar AB; Shibata N; Inoue T; Wang Y; Zhang B; Kobayashi J; Morimoto M; Saku K; Watanabe T; Fan J
Arterioscler Thromb Vasc Biol; 2009 Dec; 29(12):2047-53. PubMed ID: 19778946
[TBL] [Abstract][Full Text] [Related]
9. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia.
Guérin M; Bruckert E; Dolphin PJ; Turpin G; Chapman MJ
Arterioscler Thromb Vasc Biol; 1996 Jun; 16(6):763-72. PubMed ID: 8640404
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
Ooi EM; Watts GF; Sprecher DL; Chan DC; Barrett PH
J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786
[TBL] [Abstract][Full Text] [Related]
11. Human ApoA-II inhibits the hydrolysis of HDL triglyceride and the decrease of HDL size induced by hypertriglyceridemia and cholesteryl ester transfer protein in transgenic mice.
Zhong S; Goldberg IJ; Bruce C; Rubin E; Breslow JL; Tall A
J Clin Invest; 1994 Dec; 94(6):2457-67. PubMed ID: 7989603
[TBL] [Abstract][Full Text] [Related]
12. Triglyceridemia and peroxisome proliferator-activated receptor-alpha expression are not connected in fenofibrate-treated pregnant rats.
Soria A; González Mdel C; Vidal H; Herrera E; Bocos C
Mol Cell Biochem; 2005 May; 273(1-2):97-107. PubMed ID: 16013444
[TBL] [Abstract][Full Text] [Related]
13. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.
Fruchart JC; Duriez P
Drugs Today (Barc); 2006 Jan; 42(1):39-64. PubMed ID: 16511610
[TBL] [Abstract][Full Text] [Related]
14. Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV.
Goldberg IJ; Scheraldi CA; Yacoub LK; Saxena U; Bisgaier CL
J Biol Chem; 1990 Mar; 265(8):4266-72. PubMed ID: 2307668
[TBL] [Abstract][Full Text] [Related]
15. Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation.
Duez H; Lefebvre B; Poulain P; Torra IP; Percevault F; Luc G; Peters JM; Gonzalez FJ; Gineste R; Helleboid S; Dzavik V; Fruchart JC; Fiévet C; Lefebvre P; Staels B
Arterioscler Thromb Vasc Biol; 2005 Mar; 25(3):585-91. PubMed ID: 15618549
[TBL] [Abstract][Full Text] [Related]
16. Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome.
Vega GL; Cater NB; Hadizadeh DR; Meguro S; Grundy SM
Clin Pharmacol Ther; 2003 Sep; 74(3):236-44. PubMed ID: 12966367
[TBL] [Abstract][Full Text] [Related]
17. Beneficial effects of fibrates on apolipoprotein A-I metabolism occur independently of any peroxisome proliferative response.
Hennuyer N; Poulain P; Madsen L; Berge RK; Houdebine LM; Branellec D; Fruchart JC; Fiévet C; Duverger N; Staels B
Circulation; 1999 May; 99(18):2445-51. PubMed ID: 10318668
[TBL] [Abstract][Full Text] [Related]
18. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice.
Berthou L; Duverger N; Emmanuel F; Langouët S; Auwerx J; Guillouzo A; Fruchart JC; Rubin E; Denèfle P; Staels B; Branellec D
J Clin Invest; 1996 Jun; 97(11):2408-16. PubMed ID: 8647932
[TBL] [Abstract][Full Text] [Related]
19. Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients.
Brisson D; Ledoux K; Bossé Y; St-Pierre J; Julien P; Perron P; Hudson TJ; Vohl MC; Gaudet D
Pharmacogenetics; 2002 Jun; 12(4):313-20. PubMed ID: 12042669
[TBL] [Abstract][Full Text] [Related]
20. Fenofibrate increases very low density lipoprotein triglyceride production despite reducing plasma triglyceride levels in APOE*3-Leiden.CETP mice.
Bijland S; Pieterman EJ; Maas AC; van der Hoorn JW; van Erk MJ; van Klinken JB; Havekes LM; van Dijk KW; Princen HM; Rensen PC
J Biol Chem; 2010 Aug; 285(33):25168-75. PubMed ID: 20501652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
